inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
Company profile
Ticker
INO
Exchange
Website
CEO
Jong Kim
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENETRONICS BIOMEDICAL CORP, GENETRONICS BIOMEDICAL LTD, INOVIO BIOMEDICAL CORP
SEC CIK
Corporate docs
Subsidiaries
Inovio Asia, LLC ...
IRS number
330024450
INO stock data
Latest filings (excl ownership)
8-K
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
17 Apr 24
424B5
Prospectus supplement for primary offering
17 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
EFFECT
Notice of effectiveness
1 Feb 24
CORRESP
Correspondence with SEC
29 Jan 24
S-3/A
Shelf registration (amended)
26 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
25 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
12 Jan 24
Transcripts
INO
Earnings call transcript
2023 Q4
6 Mar 24
INO
Earnings call transcript
2023 Q3
9 Nov 23
INO
Earnings call transcript
2023 Q2
9 Aug 23
INO
Earnings call transcript
2023 Q1
10 May 23
INO
Earnings call transcript
2022 Q4
1 Mar 23
INO
Earnings call transcript
2022 Q3
8 Nov 22
INO
Earnings call transcript
2022 Q2
10 Aug 22
INO
Earnings call transcript
2022 Q1
11 May 22
INO
Earnings call transcript
2021 Q4
2 Mar 22
INO
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
David B. Weiner
28 Feb 24
4
Jacqueline Elizabeth Shea
28 Feb 24
4
Laurent Humeau
28 Feb 24
4
PETER KIES
28 Feb 24
4
Michael John Sumner
28 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
STATE STREET CORP
22 Jan 24
SC 13G/A
STATE STREET CORP
10 Jul 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
Michael John Sumner
3 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.80 mm | 18.80 mm | 18.80 mm | 18.80 mm | 18.80 mm | 18.80 mm |
Cash burn (monthly) | 11.30 mm | 265.30 k | 11.85 mm | 14.37 mm | 9.70 mm | 11.20 mm |
Cash used (since last report) | 77.87 mm | 1.83 mm | 81.65 mm | 99.04 mm | 66.86 mm | 77.18 mm |
Cash remaining | -59.07 mm | 16.98 mm | -62.85 mm | -80.23 mm | -48.05 mm | -58.38 mm |
Runway (months of cash) | -5.2 | 64.0 | -5.3 | -5.6 | -5.0 | -5.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 126 |
Opened positions | 19 |
Closed positions | 26 |
Increased positions | 22 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 21.55 bn |
Total shares | 55.50 mm |
Total puts | 40.10 k |
Total calls | 429.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 20.07 mm | $7.81 bn |
BLK Blackrock | 5.92 mm | $2.30 bn |
D. E. Shaw & Co. | 5.52 mm | $2.15 bn |
Renaissance Technologies | 4.89 mm | $1.90 bn |
Millennium Management | 4.58 mm | $1.78 bn |
Geode Capital Management | 2.75 mm | $1.07 bn |
GMT Capital | 1.51 mm | $588.75 mm |
Jacobs Levy Equity Management | 1.15 mm | $447.34 mm |
STT State Street | 871.05 k | $338.84 mm |
Two Sigma Investments | 829.24 k | $322.57 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Michael John Sumner | RSU Common Stock | Grant | Acquire A | No | No | 0 | 15,029 | 0.00 | 15,029 |
28 Feb 24 | Michael John Sumner | Common Stock Option Common Stock | Grant | Acquire A | No | No | 8.46 | 18,750 | 158.63 k | 18,750 |
28 Feb 24 | Jacqueline Elizabeth Shea | RSU Common Stock | Grant | Acquire A | No | No | 0 | 55,895 | 0.00 | 55,895 |
28 Feb 24 | Jacqueline Elizabeth Shea | Common Stock Option Common Stock | Grant | Acquire A | No | No | 8.46 | 69,733 | 589.94 k | 69,733 |
28 Feb 24 | Laurent Humeau | RSU Common Stock | Grant | Acquire A | No | No | 0 | 15,029 | 0.00 | 15,029 |
28 Feb 24 | Laurent Humeau | Common Stock Option Common Stock | Grant | Acquire A | No | No | 8.46 | 18,750 | 158.63 k | 18,750 |
28 Feb 24 | Peter Kies | RSU Common Stock | Grant | Acquire A | No | No | 0 | 15,029 | 0.00 | 15,029 |
28 Feb 24 | Peter Kies | Common Stock Option Common Stock | Grant | Acquire A | No | No | 8.46 | 18,750 | 158.63 k | 18,750 |
26 Feb 24 | David B. Weiner | Common Stock | Option exercise | Acquire M | No | No | 0 | 972 | 0.00 | 80,343 |
26 Feb 24 | David B. Weiner | Common Stock | Option exercise | Acquire M | No | No | 0 | 972 | 0.00 | 79,371 |
News
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?
16 Apr 24
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Apr 24
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
16 Apr 24
Press releases
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
15 Apr 24
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
26 Mar 24
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
6 Mar 24
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
7 Feb 24
INOVIO Reports Inducement Grant Under Inducement Plan
2 Feb 24